가미도홍사물탕 약욕요법 이후 호전된 항암화학요법 유발 수족증후군 1례
A Case Report of Chemotherapy-Induced Hand-Foot Syndrome Treated with Modified Dohongsamul-tang
1
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
Hand-foot syndrome (HFS) frequently occurs after receiving chemotherapy, such as sorafenib, in patients with hepatocellular carcinoma (HCC), and this impairs quality of life (QOL). The prevalence of HFS due to sorafenib is 10-28%. The effective methods to treat HFS are not established aside from temporary discontinuation of chemotherapy agents and drug dosage adjustment because the mechanism of HFS has not been elucidated. According to a previous study, modified Dohongsamul-tang was effective in the treatment of patients with HFS and improved patients’ QOL. Based on these results, we administered the soaking method with modified Dohongsamul-tang to a 50-year-old male patient with HCC complaining of HFS due to sorafenib. After two weeks, the symptoms of HFS were improved despite taking sorafenib. We suggest that modified Dohongsamul-tang is a novel method for treating HFS.
Abstract
Hand-foot syndrome (HFS) frequently occurs after receiving chemotherapy, such as sorafenib, in patients with hepatocellular carcinoma (HCC), and this impairs quality of life (QOL). The prevalence of HFS due to sorafenib is 10-28%. The effective methods to treat HFS are not established aside from temporary discontinuation of chemotherapy agents and drug dosage adjustment because the mechanism of HFS has not been elucidated. According to a previous study, modified Dohongsamul-tang was effective in the treatment of patients with HFS and improved patients’ QOL. Based on these results, we administered the soaking method with modified Dohongsamul-tang to a 50-year-old male patient with HCC complaining of HFS due to sorafenib. After two weeks, the symptoms of HFS were improved despite taking sorafenib. We suggest that modified Dohongsamul-tang is a novel method for treating HFS.
참고문헌 (27)
- Abushullaih S, "Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience", Cancer Invest, 20(1), pp.3~10 (2002)[DOI]
- Amy SC, "Chemotherapy-induced palmar-plantar erythrodysesthesia syndrome: etiology and emerging therapies", Support Cancer Therapy, 1(4), pp.213~218 (2004)[DOI]
- Zhao C, "Effect of modified taohongsiwu decoction on patients with chemotherapy-induced hand-foot syndrome", J Tradit Chin Med, 34(1), pp.10~14 (2014)[DOI]
- Nagore E, "Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management", Am J Clin Dermatol, 1(4), pp.225~234 (2000)[DOI]
- Baack BR, "Chemotherapy-induced acral erythema", J Am Acad Dermatol, 24(3), pp.457~461 (1991)[DOI]
- Azuma Y, "Significant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancer", Biol Pharm Bull, 35(5), pp.717~724 (2012)[DOI]
- Wehler TC, "Combination therapies with oxaliplatin and oral capecitabine or intravenous 5-FU show similar toxicity profiles in gastrointestinal carcinoma patients if hand-food syndrome prophylaxis is performed continuously", Oncol Lett, 3(6), pp.1191~1194 (2012)[DOI]
- von Gruenigen V, "A double-blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin-related hand-foot syndrome in gynecologic oncology patients", Cancer, 116(20), pp.4735~4743 (2010)[DOI]
- Wolf SL, "Placebo-controlled trial to determine the effectiveness of a urea", lactic acid-based topical keratolytic agent for prevention of capecitabine-induced Hand-Foot Syndrome: North central cancer treatment group study N05C5, 2010, pp.28(35), 5182~5187
- "Common Terminology Criteria for Adverse Events(CTCAE) v.4.0"[URL]
- McGlynn KA, "Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability", Clin Liver Dis, 19(2), pp.223~238 (2015)[DOI]
- Grandinetti CA, "Sorafenib and sunitinib: novel targeted therapies for renal cell cancer", Pharmacotherapy, 27(8), pp.1125~1144 (2007)[DOI]
- Gridelli C, "Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer", Oncologist, 12(2), pp.191~200 (2007)[DOI]
- Llovet JM, "Sorafenib in advanced hepatocellular carcinoma", N Engl J Med, 359(4), pp.378~390 (2008)[DOI]
- Lipworth AD, "Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib", Oncology, 77(4), pp.257~271 (2009)[DOI]
- Oh G, "Golden Mirror of Medicine", pp.443~ (1983), Daesungmoonhwasa
- Korean medicine pathological association, "Pathology in Korean medicine", pp.153;165~ (1998), Iljoongsa
- Korean Herbological Association, "Herbology", pp.124~ (1992), Younglimsa
- Cho DI, "The literature review for prescription of static blood", Daejeon University Korean Medicine Research Institute, 5(2), pp.265~279 (1997)
- Korean Dermatological Association, "Detmatology, 3rd ed", pp.548~ (1994), RyoMoonGak
- 조수정, "만성 어깨 통증의 한약 추출 외용 젤 치료에 대한 임상연구", Journal of Acupuncture Research, 31(4), pp.1~9 (2014), 대한침구의학회
- Moon WS, "A Historical consideration on the External Treatment theories and diseases for which medicine is efficacious", Korean Journal of Oriental Medicine, 10(2), pp.1~21 (2004)
- Wang L, "Traditional Chinese Medicine internal and external wash treatment for eight cases hand-foot syndrome caused by capecitabine", Zhong Yi Yan Jiu, 19(4), pp.41~43 (2006)
- Cho YL, "The effect of DohongSamulTang (DST) on immune-system in L1210 cells-transplanted mice", JPPKM, 13(1), pp.132~140 (1999)
- 유봉선, "산화적 손상에 의해 유발된 심근세포 독성에 대한 桃紅四物湯의 방어효과", 동의생리병리학회지, 18(5), pp.1374~1381 (2004), 한의병리학회
- Yook HS, "The Effects Of Geumguesingitang And Dohongsamultang On Rats With Nephrosis Induced By Puromycin Aminonucleoside", Journal of Korean Medicine, 18(2), pp.283~315 (1997)
- Shin DC, "The Study on the Effect of Dohongsamultang and Dansameum on Restrain of Thorombus Formation", Korean J Orient Int Med, 16(2), pp.136~145 (1995)